1 | 0.5 mg budesonide effervescent tablet for orodispersible use | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
2 | 1 mg budesonide effervescent tablet for orodispersible use | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
3 | 1mg budesonide effervescent tablet for orodispersible use | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
4 | 2mg budesonide effervescent tablet for orodispersible use | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
5 | 5 mg Montelukast | 1件: Montelukast Montelukast | 1件: D08229
D08229
| 1件: CYSLTR1 CYSLTR1 💬 | 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
6 | AK002 | - | - | - | - | 1件: 98 98 |
7 | Allergy immunotherapy (allergy shots) | - | - | - | - | 1件: 98 98 |
8 | Alpha-proteinase inhibitor | - | - | - | - | 1件: 98 98 |
9 | AMG 157 | 1件: Tezepelumab Tezepelumab | 1件: D11771
D11771
| 1件: TSLP TSLP 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 98 98 |
10 | AMG157 | - | - | - | - | 1件: 98 98 |
11 | APD334 | - | - | - | - | 5件: 93 93, 96, 97, 98, 269 |
12 | APT-1011 | - | - | - | - | 1件: 98 98 |
13 | APT-1011 - 3 mg | - | - | - | - | 1件: 98 98 |
14 | APT-1011 3 mg HS | - | - | - | - | 1件: 98 98 |
15 | AQ280 | - | - | - | - | 1件: 98 98 |
16 | AR401959 L-arginine | 1件: Arginine Arginine | 1件: D02982
D02982
| - | - | 3件: 96 96, 97, 98 |
17 | Arginine | 1件: Arginine Arginine | 1件: D02982
D02982
| - | - | 11件: 46 46, 58, 67, 78, 96, 97, 98, 113, 210, 251, 299 |
18 | Baked Milk | 1件: Cow milk Cow milk | - | - | - | 1件: 98 98 |
19 | Barzolvolimab | - | - | - | - | 1件: 98 98 |
20 | Beclomethasone dipropionate | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 1件: D00689
D00689
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 97 97, 98 |
21 | Benralizumab | 1件: Benralizumab Benralizumab | 1件: D09874
D09874
| 1件: IL5RA IL5RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 5件: 44 44, 45, 98, 162, 299 |
22 | Bethanechol | 1件: Bethanechol Bethanechol | - | - | - | 1件: 98 98 |
23 | BT | - | - | - | - | 3件: 96 96, 97, 98 |
24 | BT-11 1000mg | - | - | - | - | 3件: 96 96, 97, 98 |
25 | BT-11 500mg | - | - | - | - | 1件: 98 98 |
26 | BUDESONIDE | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 9件: 66 66, 93, 94, 95, 96, 97, 98, 228, 299 |
27 | Budesonide 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
28 | Budesonide 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
29 | Budesonide 0.5mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
30 | Budesonide 1 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
31 | Budesonide 1 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
32 | Budesonide 1 mg orodispersible tablets (BUL 1 mg) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
33 | Budesonide 1mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
34 | Budesonide 2 mg orodispersible tablets (BUL 2 mg) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
35 | Budesonide [0.4mg/ml] viscous suspension | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
36 | Budesonide Gel | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
37 | Budesonide oral suspension | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
38 | Budesonide oral suspension [0.2 mg/ml] | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
39 | Budesonide Orodispersible Tablets (Jorveza) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
40 | Budesonide plus Prevacid | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
41 | BUET 0.5 mg | - | - | - | - | 1件: 98 98 |
42 | BUET 1 mg | - | - | - | - | 1件: 98 98 |
43 | BUET 1mg | - | - | - | - | 1件: 98 98 |
44 | BUET 2mg | - | - | - | - | 1件: 98 98 |
45 | BUL 0.5 mg | - | - | - | - | 1件: 98 98 |
46 | BUL 1 mg | - | - | - | - | 1件: 98 98 |
47 | BUU 0.4mg/ml | - | - | - | - | 1件: 98 98 |
48 | CALY-002 | - | - | - | - | 1件: 98 98 |
49 | CC | - | - | - | - | 13件: 28 28, 46, 49, 51, 56, 84, 85, 96, 97, 98, 162, 202, 271 |
50 | CC-93538 | - | - | - | - | 1件: 98 98 |
51 | Cendakimab | - | - | - | - | 1件: 98 98 |
52 | Citalopram | 1件: Citalopram Citalopram | 1件: D07704
D07704
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 7件: 6 6, 8, 13, 18, 46, 98, 127 |
53 | Compressa effervescente 0,5 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
54 | Compressa effervescente 1 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
55 | Cromolyn | 1件: Cromoglicic acid Cromoglicic acid | 1件: D07753
D07753
| - | - | 3件: 2 2, 85, 98 |
56 | CYP substrates | - | - | - | - | 1件: 98 98 |
57 | Dexlansoprazole | 1件: Dexlansoprazole Dexlansoprazole | 1件: D08903
D08903
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 98 98 |
58 | Dupilumab | 1件: Dupilumab Dupilumab | 1件: D10354
D10354
| 1件: IL4R IL4R 💬 | 8件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 5件: 51 51, 97, 98, 160, 162 |
59 | Dupilumab (blinded) | 1件: Dupilumab Dupilumab | 1件: D10354
D10354
| 1件: IL4R IL4R 💬 | 8件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 98 98 |
60 | Dupilumab (open-label) | 1件: Dupilumab Dupilumab | 1件: D10354
D10354
| 1件: IL4R IL4R 💬 | 8件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 98 98 |
61 | Dupixent | 1件: Dupilumab Dupilumab | 1件: D10354
D10354
| 1件: IL4R IL4R 💬 | 8件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 3件: 98 98, 160, 162 |
62 | Else nutrition formula | - | - | - | - | 1件: 98 98 |
63 | Eosinophilic Esophagitis (E0E) food introduction-2nd | - | - | - | - | 1件: 98 98 |
64 | Eosinophilic Esophagitis (EoE) food introduction-1st | - | - | - | - | 1件: 98 98 |
65 | Eosinophilic Esophagitis (EoE) Food introduction-3rd dose | - | - | - | - | 1件: 98 98 |
66 | EP-104IAR | - | - | - | - | 1件: 98 98 |
67 | ESO-101 | - | - | - | - | 1件: 98 98 |
68 | Esomeprazole | 1件: Esomeprazole Esomeprazole | 1件: D07917
D07917
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
69 | Etrasimod | 1件: Etrasimod Etrasimod | 1件: D10930
D10930
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 3件: 96 96, 97, 98 |
70 | Etrasimod L-arginine | 2件: Arginine Arginine, Etrasimod | 2件: D02982
D02982
,
D10930
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 3件: 96 96, 97, 98 |
71 | EUR-1100 | - | - | - | - | 1件: 98 98 |
72 | Famotidine | 1件: Famotidine Famotidine | 1件: D00318
D00318
| 1件: HRH2 HRH2 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬 | 5件: 6 6, 46, 86, 98, 107 |
73 | Fasenra | 1件: Benralizumab Benralizumab | 1件: D09874
D09874
| 1件: IL5RA IL5RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 5件: 44 44, 45, 98, 162, 299 |
74 | Florence 30 µg/mL | - | - | - | - | 1件: 98 98 |
75 | Florence 60 µg/mL | - | - | - | - | 1件: 98 98 |
76 | Florence 90 µg/mL | - | - | - | - | 1件: 98 98 |
77 | Flovent | - | - | - | - | 1件: 98 98 |
78 | Fluticasone | 1件: Fluticasone Fluticasone | 1件: D07981
D07981
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 98 98, 228, 299 |
79 | Fluticasone MDI | 1件: Fluticasone Fluticasone | 1件: D07981
D07981
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
80 | FLUTICASONE PROPIONATE | 2件: Fluticasone Fluticasone, Fluticasone propionate | 2件: D01708
D01708
,
D07981
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 98 98, 228 |
81 | Fluticasone Propionate, USP | 1件: Fluticasone propionate Fluticasone propionate | 1件: D01708
D01708
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
82 | Gold | 1件: Gold Gold | - | - | - | 43件: 2 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 63, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 167, 171, 193, 218, 222, 224, 226, 227, 230, 271, 291, 296, 298, 310, 318 |
83 | High dose budesonide suspension | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
84 | High dose budesonide tablet | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
85 | Infliximab | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 26件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
86 | Inhaled/swallowed budesonide | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
87 | Intubated with Propofol (IP) | 1件: Propofol Propofol | 1件: D00549
D00549
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 98 98 |
88 | Intubated with Sevoflurane (IS) | 1件: Sevoflurane Sevoflurane | 1件: D00547
D00547
| - | - | 1件: 98 98 |
89 | IRL201104 | - | - | - | - | 1件: 98 98 |
90 | Jorveza | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
91 | Jorveza 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
92 | Jorveza 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
93 | Jorveza 1 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
94 | Jorveza 1 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
95 | L-arginine | 2件: Arginine Arginine, L-arginine | 1件: D02982
D02982
| - | - | 8件: 46 46, 67, 78, 96, 97, 98, 113, 299 |
96 | Lansoprazole | 1件: Lansoprazole Lansoprazole | 1件: D00355
D00355
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 7件: 63 63, 71, 85, 98, 166, 222, 299 |
97 | Lirentelimab | 1件: Lirentelimab Lirentelimab | 1件: D11906
D11906
| 1件: SIGLEC8 SIGLEC8 💬 | - | 1件: 98 98 |
98 | Lirentelimab (AK002) | 1件: Lirentelimab Lirentelimab | 1件: D11906
D11906
| 1件: SIGLEC8 SIGLEC8 💬 | - | 1件: 98 98 |
99 | Loratadine | 1件: Loratadine Loratadine | 1件: D00364
D00364
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 4件: 13 13, 46, 89, 98 |
100 | Losartan | 1件: Losartan Losartan | 1件: D08146
D08146
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 17件: 17 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
101 | LOSARTAN POTASSIUM | 2件: Losartan Losartan, Potassium | 2件: D08146
D08146
,
D08403
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 5件: 36 36, 98, 167, 179, 215 |
102 | Low dose budesonide tablet | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
103 | MEDI-563 | - | - | - | - | 5件: 44 44, 45, 98, 162, 299 |
104 | MEDI9929 | 1件: Tezepelumab Tezepelumab | 1件: D11771
D11771
| 1件: TSLP TSLP 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 98 98 |
105 | MEDI9929 anti-TSLP mAb (AMG157) | 1件: Tezepelumab Tezepelumab | 1件: D11771
D11771
| 1件: TSLP TSLP 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 98 98 |
106 | MEPOLIZUMAB | 1件: Mepolizumab Mepolizumab | 1件: D04923
D04923
| 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 4件: 44 44, 45, 98, 162 |
107 | Mepolizumab 100 mg | 1件: Mepolizumab Mepolizumab | 1件: D04923
D04923
| 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 98 98 |
108 | Mepolizumab 300 mg | 1件: Mepolizumab Mepolizumab | 1件: D04923
D04923
| 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 98 98 |
109 | Mesalamine | 1件: Mesalazine Mesalazine | 1件: D00377
D00377
| - | - | 4件: 96 96, 97, 98, 164 |
110 | Mesalamine Oral Product | 1件: Mesalazine Mesalazine | 1件: D00377
D00377
| - | - | 1件: 98 98 |
111 | Milk | 1件: Cow milk Cow milk | - | - | - | 1件: 98 98 |
112 | Mometasone | 1件: Mometasone Mometasone | 1件: D08227
D08227
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 98 98, 162 |
113 | MOMETASONE FUROATE | 2件: Mometasone Mometasone, Mometasone furoate | 2件: D00690
D00690
,
D08227
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 98 98, 162 |
114 | Montelukast | 1件: Montelukast Montelukast | 1件: D08229
D08229
| 1件: CYSLTR1 CYSLTR1 💬 | 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | 8件: 6 6, 13, 46, 61, 63, 85, 98, 228 |
115 | Montelukast/ Singulair | 1件: Montelukast Montelukast | 1件: D08229
D08229
| 1件: CYSLTR1 CYSLTR1 💬 | 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
116 | Nasonex | - | - | - | - | 1件: 98 98 |
117 | OC000459 | - | - | - | - | 1件: 98 98 |
118 | OMALIZUMAB | 1件: Omalizumab Omalizumab | 1件: D05251
D05251
| 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 7件: 46 46, 53, 65, 98, 162, 226, 299 |
119 | Oral Budesonide | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
120 | Oral Budesonide Suspension (MB-9) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
121 | Oral Budesonide Suspension (OBS) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
122 | Oral cromolyn sodium | 1件: Cromoglicic acid Cromoglicic acid | 1件: D07753
D07753
| - | - | 1件: 98 98 |
123 | Oral Viscous Budesonide | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
124 | Oral Viscous Budesonide (OVB) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
125 | Picoprep | - | - | - | - | 1件: 98 98 |
126 | Potassium | 1件: Potassium Potassium | 1件: D08403
D08403
| - | - | 13件: 36 36, 46, 66, 67, 88, 93, 94, 98, 115, 167, 179, 215, 235 |
127 | PROPOFOL | 1件: Propofol Propofol | 1件: D00549
D00549
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 8件: 6 6, 21, 22, 34, 46, 70, 98, 296 |
128 | QAX576 | - | - | - | - | 4件: 51 51, 85, 96, 98 |
129 | Reslizumab | 1件: Reslizumab Reslizumab | 1件: D08985
D08985
| 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 2件: 44 44, 98 |
130 | RPC4046 | - | - | - | - | 1件: 98 98 |
131 | SB-240563 | - | - | - | - | 3件: 44 44, 45, 98 |
132 | SCH55700 | - | - | - | - | 1件: 98 98 |
133 | Sevoflurane | 1件: Sevoflurane Sevoflurane | 1件: D00547
D00547
| - | - | 7件: 6 6, 21, 22, 34, 98, 225, 296 |
134 | Sirolimus | 1件: Sirolimus Sirolimus | 1件: D00753
D00753
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 35件: 13 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 300, 331 |
135 | Steroid and Proton Pump Inhibitor Therapy | - | - | - | - | 1件: 98 98 |
136 | Sucralfate | 1件: Sucralfate Sucralfate | 1件: D00446
D00446
| - | - | 1件: 98 98 |
137 | Swallowed fluticasone | 1件: Fluticasone Fluticasone | 1件: D07981
D07981
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
138 | Tezepelumab | 1件: Tezepelumab Tezepelumab | 1件: D11771
D11771
| 1件: TSLP TSLP 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 98 98 |
139 | Tezepelumab via APFS | 1件: Tezepelumab Tezepelumab | 1件: D11771
D11771
| 1件: TSLP TSLP 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 98 98 |
140 | Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms | 1件: Lansoprazole Lansoprazole | 1件: D00355
D00355
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 98 98 |
141 | Viaskin Milk 500 mcg | 1件: Cow milk Cow milk | - | - | - | 1件: 98 98 |
142 | Viscous/swallowed budesonide | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
143 | Vonoprazan | 1件: Vonoprazan Vonoprazan | 1件: D11784
D11784
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 2件: 63 63, 98 |
144 | Zofran - no intubation | - | - | - | - | 1件: 98 98 |